BOPI 05 BR / 2025 REPERTOIRE NUMERIQUE 16 Fig. 1 ________________________________________ (11) 21894 Consulter le mémoire (51) A61K 31/417 (2023.01); A61K 31/4184 (2023.01); A61K 31/517 (2023.01) (21) 1202300467 - PCT/US2022/030690 (22) 24/05/2022 (30) US n° 63/192,822 du 25/05/2021 (54) Imidazole-Containing Inhibitors Of ALK2 Kinase. (72) BABU, Yarlagadda, S. (US); KOTIAN, Pravin, L. (US); ZHANG, Weihe (US); LU, Peng-Cheng (US); SPAULDING, Andrew, E. (US); LV, Wei (US) et RAMAN, Krishnan (US) (73) BIOCRYST PHARMACEUTICALS, INC., 4505 Emperor Blvd., Suite 200, DURHAM, NC 27703 (US) (74) Cabinet SPOOR & FISHER Inc. NGWAFOR & PARTNERS SARL, The House of Gideon, Golf/Bastos Quater, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva. Formula I ; Formula II ; Formula III ;
RkJQdWJsaXNoZXIy MTM1NDc3MA==